(Q45916609)

17 December 2017

meta-analysis

0 references

title

Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. (English)

1 reference

17 December 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

Meghan Brennan

1

1 reference

17 December 2017

J Andrew Williams

2

1 reference

17 December 2017

Ying Chen

3

1 reference

17 December 2017

Michael Tortorici

4

1 reference

17 December 2017

Yazdi Pithavala

5

1 reference

17 December 2017

Yingxue Cathy Liu

6

1 reference

17 December 2017

publication date

15 December 2011

1 reference

17 December 2017

European Journal of Clinical Pharmacology

published in

1 reference

17 December 2017

volume

68

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

645-655

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1007/s00228-011-1171-8

exact match

0 references

cites work

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

21 January 2018

Axitinib (AG-013736).

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

PhRMA white paper on ADME pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

The missing linkage: what pharmacogenetic associations are left to find in CYP3A?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

A significant drug-metabolizing role for CYP3A5?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1171-8

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population

21 January 2018

1 reference

12 December 2020

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

1 reference

12 December 2020

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

1 reference

12 December 2020

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

1 reference

12 December 2020

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.

1 reference

12 December 2020

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

12 December 2020

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

1 reference

12 December 2020

MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders

1 reference

12 December 2020

10.1007/S00228-011-1171-8

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

1005787394

0 references

Fatcat ID

release_z5dlndiqtjhjvd33pak36eykn4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/z5dlndiqtjhjvd33pak36eykn4

24 November 2022

mapped directly with Wikidata item

1 reference

17 December 2017